Skip to main content

Table 1 Patient demographics and disease characteristics at baseline

From: A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

Parameter

LY2603618/gemcitabine

Gemcitabine

(n = 65)

(n = 34)

Age, years

 Mean (SD)

64.3 (8.3)

64.4 (10.1)

 Median

64.0

65.5

 Range

47–83

39–90

Gender, n (%)

 Female

23 (35.4)

14 (41.2)

 Male

42 (64.6)

20 (58.8)

Race, n (%)

  

 White

62 (95.4)

32 (94.1)

 Black or African American

2 (3.1)

2 (5.9)

 American Indian or Alaska Native

1 (1.5)

0

BSA at baseline (m2)

 Mean (SD)

1.8 (0.2)

1.8 (0.2)

 Median

1.8

1.7

 Range

1.3–2.5

1.4–2.5

Disease stage, n (%)

 II

6 (9.2)

3 (8.8)

 III

8 (12.3)

5 (14.7)

 IV

50 (76.9)

26 (76.5)

 Unknown

1 (1.5)

0

ECOG PS, n (%)

 0

28 (43.1)

14 (41.2)

 1

31 (47.7)

17 (50)

 2

6 (9.2)

3 (8.8)

  1. BSA body mass index; ECOG PS Eastern Cooperative Oncology Group performance status; LY2603618/gemcitabine LY2603618 (230 mg flat dose) combined with gemcitabine 1000 mg/m2; m 2 meters squared; mg milligrams; n number of patients; SD standard deviation